HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herbal cancer cure claims

This article was originally published in The Tan Sheet

Executive Summary

David Walker, d/b/a DLW Consulting, permanently barred from representing dietary supple-ments, devices as "effective in treating and curing cancer" or as making "surgery, chemotherapy and other conventional cancer treatments unnecessary" absent competent and reliable scientific evidence, according to stipulated judgment signed by Tacoma, Wash. federal judge Oct. 23. In case brought by FTC, Walker also is required to turn over to commission customers' names, addresses; judgment includes monetary penalty if Walker made "material misrepresentations or omissions" in his financial disclosure form. FTC sued Walker in March related to cancer claims for CWAT-Treatment: BioResonance Therapy, which included dietary supplements (1"The Tan Sheet" April 8, 2002, p. 14). 2FTC press release notes Walker was required to pay $229,000 in consumer restitution under companion case brought by Washington AG...

Related Content

Topics

UsernamePublicRestriction

Register

RS131036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel